Successful Treatment of MuSK Antibody-Positive Myasthenia Gravis with Rituximab

Sen A. D. Y., BAYSAL A., Aydin O. U., ÇARMAN K. B., YARAR C.

JOURNAL OF CHILD - COCUK DERGISI, cilt.25, sa.3, ss.172-175, 2025 (ESCI, TRDizin) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25 Sayı: 3
  • Basım Tarihi: 2025
  • Doi Numarası: 10.26650/jchild.2025.1704940
  • Dergi Adı: JOURNAL OF CHILD - COCUK DERGISI
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.172-175
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Muscle-specific tyrosine kinase antibody-associated myasthenia gravis (MuSK-MG) is a rare subtype of MG distinguished by recurring relapses and a clinical history unresponsive to conventional therapies. Rituximab, a monoclonal antibody that targets CD20+ B cells, has effectively induced long-term remission in adults. We report a pediatric MuSK-MG patient who exhibited a favourable response to rituximab following the ineffectiveness of steroid therapy and acetylcholinesterase inhibitor (AChEI) therapy.